Adventrx Pharmaceuticals Inc. (ANX) reported that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere.
Shin Poong Pharmaceuticals, Adventrx's partner for ANX-514 in South Korea, independently conducted the study and data analysis.
The company said, "We intend next to conduct a separate clinical bioequivalence study of ANX-514 in South Korea and look forward to continuing to work with ADVENTRX toward the possible commercialization of ANX-514 in both the U.S. and South Korea."
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.